Rallybio Corporation Insider Trading

RLYB

Last 12 months

Insiders sold 14K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chief Financial Officer Jonathan I Lieber sold 4K on Feb 23, 16% of their stake, outside a plan. The last open-market buy by an executive or director was in Mar 2023.

Net open-market

−14K

0 buys · 2 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 1

executives and directors

Last open-market buy

Mar 2023

Mar 14, 2023

Get an email when RLYB's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 27	Jonathan I Lieber Chief Financial Officer	SoldNo plan	599	$16.04	10K	3.7%	Form 4
May 18 – 19	Adar1 Capital Management, LLC Large holder	Bought 3 parts	16,209	$13.98 average	227K	1.8%	Form 4
May 13 – 15	Daniel Schneeberger Large holder	Bought 4 parts	79,559	$13.99 average	$1.11M	9.6%	Form 4
May 11 – 12	Adar1 Capital Management, LLC Large holder	Bought 4 parts	50,800	$14.00 average	711K	6.5%	Form 4
May 4 – 5	Daniel Schneeberger Large holder	Bought 3 parts	155,905	$13.98 average	$2.18M	25%	Form 4
Feb 23	Jonathan I Lieber Chief Financial Officer	SoldNo plan	789	$5.06	4K	16%	Form 4

Oct 27No plan
Jonathan I Lieber
Chief Financial Officer · sold 599 at $16.04
10K
3.7% of stake
May 18 – 19
Adar1 Capital Management, LLC
Large holder · bought 16,209 at avg $13.98
227K
1.8% of stake
May 13 – 15
Daniel Schneeberger
Large holder · bought 79,559 at avg $13.99
$1.11M
9.6% of stake
May 11 – 12
Adar1 Capital Management, LLC
Large holder · bought 50,800 at avg $14.00
711K
6.5% of stake
May 4 – 5
Daniel Schneeberger
Large holder · bought 155,905 at avg $13.98
$2.18M
25% of stake
Feb 23No plan
Jonathan I Lieber
Chief Financial Officer · sold 789 at $5.06
4K
16% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RLYB, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with RLYB

CompareIntrinsic value

MNOVMediciNova Inc.

$1.45+2.11%40

CANFCan-Fite BioPharma Ltd.

$1.67+3.02%20

VYNEVyne Therapeutics Inc.

$14.91-18.84%25

LIPOLipella Pharmaceuticals Inc.

$0.00+0.00%25

IMNNImunon, Inc.

$0.91+0.78%10

MREOMereo BioPharma Group plc

$0.30+4.12%10

PVCTProvectus Biopharmaceuticals, Inc.

$0.05-2.00%16

CRVOCervoMed Inc.

$1.56+0.65%10

Held by ETFs

RLYB is in 1 US ETF. The largest of them, with RLYB's weight in each:

iShares Micro-Cap ETFIWC0.01%of the fund

Spot a number that looks wrong? Check it in RLYB's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RLYB

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.